



Oded Green

Partner

Pittsburgh
+1.412.355.6584

oded.green@klgates.com

OVERVIEW

Oded represents emerging growth companies in a variety of fields related to technology, biotechnology, software, robotics, and other technologies throughout their entire cycle of growth, in connection with their financings, venture capital investments, mergers and acquisitions, licensing, joint ventures, and commercial contracts. Oded also represents strategic investors, funds, and other investors.

Oded currently serves as the practice group coordinator for the Emerging Growth and Venture Capital practice group, with members spread across the globe. Prior to joining the firm, Oded practiced corporate law in Israel. He is fluent in Hebrew.

SPEAKING ENGAGEMENTS

- Panel Moderator, "Syndication of Investments," Angel Capital Association (ACA), Philadelphia, October 2021.
- Podcast Host, "M&A in the U.S. during the Coronavirus Era," Calcalist, 5 May 2020.
- Podcast Host, "What do Israeli Companies Need to Know about Delaware Corporate Law," Calcalist, 31 March 2020.
- Panel member, K&L's Global GC Roundtable, webinar, 10 June 2020.
- Frequent speaker on topics related to commercialization of technologies and spin-offs.

EDUCATION

- J.D., Chicago-Kent College of Law, Illinois Institute of Technology, 2005 (*with honors*)
- Certificate, Northwestern University, 2001 (*Certificate in Business Administration, Kellogg Graduate School of Management*)
- LL.M., Northwestern University Pritzker School of Law, 2001 (*with honors*)
- LL.B., Tel Aviv University School of Law, 1995

ADMISSIONS

- Bar of Israel
- Bar of New York
- Bar of Pennsylvania

LANGUAGES

- Hebrew

OTHER PUBLICATIONS

- “Trends, challenges and opportunities in Pittsburgh's startup market,” April 2023

NEWS & EVENTS

- 1 September 2021, K&L Gates Advises Megaport (USA) Inc. in Acquisition of InnovoEdge Inc.
- 12 October 2020, K&L Gates Advises AI Health Startup Abridge on \$15 Million Fundraising and Mobile App Global Launch

AREAS OF FOCUS

- Emerging Growth and Venture Capital
- Technology Transactions and Sourcing
- Mergers and Acquisitions

INDUSTRIES

- Life Sciences
- Technology

REPRESENTATIVE EXPERIENCE

Venture Capital Transactions; Strategic Investments

- Represented Knopp Biosciences LLC in the launch of Areteia Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with Population Health Partners, and a subsequent venture capital financing led by Bain Capital in an amount of up to US\$350 million.
- Represented a university in its structuring of an early-stage accelerator for life sciences companies.

- Represented an early-stage venture capital fund focusing in the AI health care space in its capital raise and investment in portfolio companies.
- Represented an organ regeneration biotechnology company in three rounds of venture capital investments.
- Represented a non-for-profit that develops an OTC drug for the treatment of opioid overdose in its funding by a pharmaceutical company under bankruptcy.
- Represented a public benefit corporation that transforms plastic waste from the developing world into socially and environmentally responsible fabric in connection with several rounds of offerings to a venture capital fund, foundations, and nonprofit organizations.
- Represented an insurance company in its US\$150 million investment in a fund.
- Represented an organ regeneration biotechnology company in its financing led by two venture capital funds and a related license agreement with an academic institution.
- Represented a company in the healthcare AI space, in its Series A round of financing.
- Structured the formation and fundraise of a fund for the purchase and reconstruction of distressed real estate properties.
- Represented a technology company in the railroad industry in connection with several rounds of private offerings, and a related joint venture arrangement with a public railroad company.

Mergers and Acquisitions

- Represented Immunetrics Inc., a bio-simulation company, in its sale to Simulations Plus (NASDAQ: SLP).
- Represented Knopp Biosciences, a drug discovery company, in the sale of its subsidiary to Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), with US\$100 million closing payment (cash and stock) plus earn-out payments of up to US\$1.1 billion+ scaled royalties.
- Represented Megaport Limited, an Australian network-as-a-service company, in its acquisition of Innovoedge Inc., an AI multi-cloud and edge application emerging growth technology company.
- Represented Reventics, Inc., a health care CDI and RCM company, in its sale to Omega Healthcare.
- Represented Singapore Technologies Kinetics in its acquisition of Aethon, a developer of autonomous mobile robots for manufacturing environments, hospitals, and other commercial settings.
- Represented CardiacAssist dba Tandem Life, a medical device company, in its sale to LivaNova (US\$250 million).
- Represented Jvion, a software company in the AI health care space, in connection with a growth equity investment of JMI.
- Represented Knopp Neurosciences Inc. in its US\$355 million strategic license with Biogen Idec, Inc. for Knopp's ALS Drug.

- Represented a university in the sale of its portfolio of software, education, internet, and technology companies.
- Represented Atlantic Plywood Corporation, a wholesale supplier of hardwood plywood and panel products, in its sale to Parksite Inc.
- Represented a construction software company in connection with the sale of its business.

Commercial Contracts

- Represented an organ regeneration company in its licensing of technology, clinical trials, research and development, and other commercial needs.
- Advised a global company in connection with its contract lifecycle management (distribution, sales, and supply).
- Drafted a full set of commercial contracts for a provider of a SaaS-based online fraud detection platform and a provider of a SaaS-based automated translation platform.
- Represented a video games company in its negotiations of a joint development and commercialization agreement with an education toy company.
- Represented a high-tech baby gear company in the license of its technology to a global toy manufacturer (US\$215 million).
- Represented a technology company in the railroad industry in connection with several rounds of private offerings, and a related joint venture arrangement with a public railroad company.
- Represented a developer of an OTC drug for the treatment of opioid overdose in its development, clinical testing, and production arrangements.
- Represented a diagnostic company in a joint development agreement related to the development, production, and supply of molecularly imprinted nanoparticles.
- Represented a company that develops RFID storage and tracking solutions for healthcare providers in connection with its commercialization and marketing agreement with a multinational pharmaceutical and life sciences company.

Israeli Related Matters

- Represented TDJ Pitango Ventures, a Polish-Israeli venture capital, in its investment in Cosmose, a marketing software company.
- Represented TDJ Pitango Ventures, a Polish-Israeli venture capital fund, in its investment in Neptune.ml, a developer of machine learning models.
- Represented a Singapore-based transportation company in its investment in a US venture capital fund. The funds will be used for investment in Israel-based mobility automotive start-up companies.
- Represented a venture capital firm focusing on ophthalmology in connection with its investment in an Israeli company (Series B round).

- Represented a Chinese venture capital fund in its investment in an Israeli company that develops and supplies ceramic and metal additive manufacturing technologies and solutions.
- Represented a Chinese venture capital fund in its investment in an Israeli company that develops a quick charging battery for the use with phones, electric cars, and other non-wired devices.
- Represented a US company in connection with its on-going relationship with the Israeli Railroad Company.